Latest Conference Content

Fernando Holguin, MD, describes the relationship between comorbid metabolic syndrome and pulmonary disease.

Lou Garrison, PhD, professor emeritus in the Department of Pharmacy at the University of Washington, explains what is needed to optimize use of health technology assessment (HTA) in the fragmented US health care system.

During the ATS 2021 International Conference, several studies shed new light on 2 asthma biologics.

J. Jaime Caro, MDCM, FACP, FRCPC, is chief scientist at Evidera, professor in practice at London School of Economics, and adjunct professor of medicine, epidemiology, and biostatistics at McGill University.

The study presented during the American College of Cardiology's 70th Scientific Session called for one group of hospitals to receive special audits and guidance aimed at improving care of patients with heart failure.

The e-cigarette or vaping product use–associated lung injury epidemic helped jumpstart the regulation of flavored e-cigarettes, said Laura Crotty Alexander, MD, ATSF.

Sessions, posters, and late-breaking trials at the American College of Cardiology’s 70th Scientific Session offer updates on vericiguat, SGLT2 inhibitors, sacubitril/valsartan, and heart failure therapies still in the pipeline.

Two posters presented at Virtual ISPOR 2021 analyzed the health care resource utilization and cost of patients with chronic obstructive pulmonary disease (COPD) with pneumonia, as well as the cost savings of treating patients with frequent or severe COPD exacerbations with a fixed-dose triple therapy.

There was consistent, and significant, benefit across all categories of ejection fraction—preserved, reduced, and midrange—but especially among those with preserved ejection fraction, noted Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital Heart & Vascular Center.

Vivian Lee, MD, PhD, MBA, president of health platforms, Verily Life Sciences, discusses examples of health economics and outcomes research (HEOR) use amid the pandemic to optimize patient care, as well as what impact HEOR may have in the transition to a value-based health care system.

Joe Zein, MD, PhD, outlines how sex and age differences can impact asthma disease course.

There is a possible link between psychological distress and inflammatory markers in younger patients with a history of cardiovascular (CV) disease, specifically myocardial infarction, said Mariana Garcia, MD, cardiology fellow at Emory University.

Stephanie Lovinsky-Desir, MD, MS, discusses the importance of addressing social determinants of health (SDOH) to improve outcomes in pediatric respiratory health.

Two top cardiologists debated evidence involving one clinical trial for omega-3 fatty acids, with implications for another, the REDUCE-IT study for icosapent ethyl (Vascepa).

Genome-wide association studies are building the potential for precision medicine for children with respiratory diseases, but the progress also comes with challenges related to cost and issues with early screening, according to speakers at the ATS 2021 International Conference.

Anthony Fauci, MD, told attendees at the ATS 2021 International Conference that the real-world evidence of vaccines against SARS-CoV-2, the virus that causes COVID-19, is even better than expected.

Heart failure is clearly syndromic, with several phenotypes, so it will remain challenging to reconcile patient to therapy until these unique phenotypes can be studied, stated Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine.

The study looked at dapagliflozin's benefits in the acute illness setting, specifically organ protection, according to Mikhail N. Kosiborod, MD, vice president of Research at Saint Luke's Health System.

The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic conditions, might be similarly useful in an acute setting.

A pediatric infectious disease expert reviewed some developments in the vaccine development pipeline, especially new efforts targeting infant health through maternal immunizations.

Patients with hypertrophic cardiomyopathy (HCM) had symptomatic, functional, and structural biomarker changes over the course of a little more than 6 months, explained Jay Edelberg, MD, PhD, head of Heart Failure and Cardiomyopathy Development at Bristol Myers Squibb.

ADAPTABLE was an opportunity to accomplish a large-scale study in a generalizable manner: directly involve patients, partner with them, and cocreate the program, noted Schuyler Jones, MD, associate professor of medicine at Duke University.

The investigational drug for obstructive hypertrophic cardiomyopathy is in front of FDA, with an approval target date of January 28, 2022.

Farrah Kheradmand, MD, gives an overview of her research on the mechanisms of vaping-associated lung injuries.

Results presented at the American College of Cardiology's 70th Scientific Session show most patients prefer a smaller dose and are more likely to stick with it.

Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington, previews the layout of the virtual 2021 ISPOR annual conference and the myriad of upcoming discussions.

Fernando Holguin, MD, explains the mechanisms that account for increased risk of pulmonary disease among individuals with metabolic syndrome.

Panelists of a session at the Pharmacy Quality Alliance 2021 Annual Meeting explore how shared decision-making and patient decision aids can promote appropriate care and treatment adherence, as well as lower cost and utilization of health care services.